According to Biologicaldrugreport.com, ?This is the second Phase III study to show positive results for Humira, a biologic currently approved for treatment of rheumatoid arthritis, and Abbott Laboratories said it intends to file during the first half of this year for U.S. and European regulatory approval for Humira in psoriasis. Two other biologics used to treat rheumatoid arthritis, Amgen Inc.'s Enbrel and Centocor's Remicade, have already received FDA approval for treating psoriasis.?

In the recent study, 1200 patients plagued with moderate to severe psoriasis were randomly given doses of Humira every other week or received a placebo.

The results of the study concluded that 71% of the patients that received Humira showed at least 75% improvement over normal signs of the disease after the 16 week treatment cycle.

The article also states, ?Humira patients who achieved at least a 75 percent improvement at week 16 continued to receive the biologic, and at week 33, the 490 patients who maintained their 75 percent improvement were randomized to either continue receiving Humira or a placebo. At the end of one-year, 28 percent of patients receiving the placebo had seen their condition deteriorate significantly compared to 5 percent of patients who stayed on Humira, according to the researchers.?

The results showed that Humira was statistically better at treating psoriasis than the current standard methods used to treat the disease. Humira has a great chance to potentially be approved for the treatment of psoriasis.

Click here for more information on ordering<---****HYPERLINK****--->?http://www.epharmacies.com?> online prescriptions from discount pharmacies.